Tanvex BioPharma, Inc. (6541.TW)
TWD 61.1
(2.52%)
TWD 61.1
(2.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.16 Billion TWD | 15.73% |
| 2022 | 1.58 Billion TWD | -1.03% |
| 2021 | 1.6 Billion TWD | -23.67% |
| 2020 | 2.09 Billion TWD | -9.81% |
| 2019 | 2.32 Billion TWD | 19.36% |
| 2018 | 1.95 Billion TWD | 39.01% |
| 2017 | 1.4 Billion TWD | 3.82% |
| 2016 | 1.35 Billion TWD | 62.45% |
| 2015 | 831.95 Million TWD | 78.95% |
| 2014 | 464.89 Million TWD | 54.27% |
| 2013 | 301.34 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 290.47 Million TWD | 3.49% |
| 2024 Q1 | 350.29 Million TWD | -15.13% |
| 2023 Q4 | 412.73 Million TWD | -19.3% |
| 2023 Q2 | 512.12 Million TWD | -20.01% |
| 2023 FY | 1.83 Billion TWD | 15.73% |
| 2023 Q3 | 511.46 Million TWD | -0.13% |
| 2023 Q1 | 640.23 Million TWD | 38.66% |
| 2022 Q2 | 418.42 Million TWD | 33.41% |
| 2022 Q4 | 461.73 Million TWD | 17.68% |
| 2022 Q3 | 392.36 Million TWD | -6.23% |
| 2022 Q1 | 313.63 Million TWD | -7.89% |
| 2022 FY | 1.58 Billion TWD | -1.03% |
| 2021 Q4 | 340.48 Million TWD | -12.44% |
| 2021 FY | 1.6 Billion TWD | -23.67% |
| 2021 Q2 | 459.73 Million TWD | 11.14% |
| 2021 Q1 | 413.65 Million TWD | -10.17% |
| 2021 Q3 | 388.85 Million TWD | -15.42% |
| 2020 Q4 | 460.51 Million TWD | 1.57% |
| 2020 Q1 | 623.83 Million TWD | 14.75% |
| 2020 Q2 | 561.97 Million TWD | -9.92% |
| 2020 Q3 | 453.39 Million TWD | -19.32% |
| 2020 FY | 2.09 Billion TWD | -9.81% |
| 2019 Q4 | 543.66 Million TWD | -22.28% |
| 2019 Q1 | 536.08 Million TWD | 13.35% |
| 2019 FY | 2.32 Billion TWD | 19.36% |
| 2019 Q2 | 548.91 Million TWD | 2.39% |
| 2019 Q3 | 699.49 Million TWD | 27.43% |
| 2018 Q3 | 484.9 Million TWD | -25.92% |
| 2018 FY | 1.95 Billion TWD | 39.01% |
| 2018 Q2 | 654.57 Million TWD | 93.58% |
| 2018 Q1 | 338.14 Million TWD | -12.02% |
| 2018 Q4 | 472.95 Million TWD | -2.46% |
| 2017 Q1 | 356.14 Million TWD | -24.82% |
| 2017 Q2 | 353.77 Million TWD | -0.66% |
| 2017 FY | 1.4 Billion TWD | 3.82% |
| 2017 Q3 | 308.89 Million TWD | -12.69% |
| 2017 Q4 | 384.35 Million TWD | 24.43% |
| 2016 FY | 1.35 Billion TWD | 62.45% |
| 2016 Q2 | 303.55 Million TWD | 15.75% |
| 2016 Q3 | 312.02 Million TWD | 2.79% |
| 2016 Q4 | 473.69 Million TWD | 51.81% |
| 2016 Q1 | 262.25 Million TWD | 5.56% |
| 2015 Q2 | 169.49 Million TWD | 0.0% |
| 2015 Q4 | 248.44 Million TWD | 0.08% |
| 2015 Q3 | 248.23 Million TWD | 46.46% |
| 2015 Q1 | 169.49 Million TWD | 49.28% |
| 2015 FY | 831.95 Million TWD | 78.95% |
| 2014 Q4 | 113.53 Million TWD | 0.0% |
| 2014 Q2 | 15.69 Million TWD | 0.0% |
| 2014 Q1 | 15.69 Million TWD | 0.0% |
| 2014 FY | 464.89 Million TWD | 54.27% |
| 2014 Q3 | 113.53 Million TWD | 623.56% |
| 2013 FY | 301.34 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Apex Biotechnology Corp. | 389.4 Million TWD | -454.815% |
| Sinphar Pharmaceutical Co.,Ltd. | 807.86 Million TWD | -167.426% |
| Panion & Bf Biotech Inc. | 817.56 Million TWD | -164.253% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 437.58 Million TWD | -393.724% |
| GenMont Biotech Incorporation | 204.2 Million TWD | -957.987% |
| Abnova (Taiwan) Corporation | 126.72 Million TWD | -1604.888% |
| Adimmune Corporation | 1.13 Billion TWD | -90.569% |
| Polaris Group | -3.06 Million TWD | 70587.798% |
| Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | -708.964% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -11971.582% |
| PELL Bio-Med Technology Co. Ltd. | 385.1 Million TWD | -461.002% |